Medicare Part D coverage · deflazacort · RxCUI 2716704
deflazacort 18 MG Oral Tablet [Jaythari]
Per the CMS 2026 Part D formulary file, deflazacort 18 MG Oral Tablet [Jaythari] is covered by 777 Medicare Part D plans (15.4% of enrollable products), averaging Tier 4, with prior authorization required on 91.7% of covering formularies.
- 15.4%
- Plan coverage
- 777
- Plans covering
- T4
- Avg tier
- 91.7%
- Prior auth required
What the CMS Formulary Data Shows for deflazacort 18 MG Oral Tablet [Jaythari]
Per the CMS 2026 Part D formulary file, deflazacort 18 MG Oral Tablet [Jaythari] (RxNorm concept RXCUI 2716704, generic name deflazacort) appears on 12 distinct formulary files spanning 777 Medicare Part D plan offerings - 15.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.
Real-world access to deflazacort 18 MG Oral Tablet [Jaythari] depends on utilization management as much as tier placement: 91.7% of covering formularies require prior authorization. 0% require step therapy. 8.3% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 99 Part D beneficiaries filled deflazacort 18 MG Oral Tablet [Jaythari] in 2023, with total plan-and-beneficiary spending of $15,369,330 and an average per-beneficiary annual cost of $155,245.76. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry deflazacort 18 MG Oral Tablet [Jaythari] today.
Coverage Details
- Formularies covering
- 12
- Plans covering
- 777
- Coverage rate
- 15.4%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 91.7% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 8.3% of formularies
2023 Medicare Spending
- Beneficiaries
- 99
- Total spending
- $15,369,330
- Avg per beneficiary
- $155,245.76
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering deflazacort 18 MG Oral Tablet [Jaythari]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CalOptima Health OneCare Complete (HMO D-SNP) | Orange County Health Authority | T1 | Yes | $0 | CA |
| Mass General Brigham SCO (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | Yes | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | Yes | $0 | MA |
| UHC Dual Complete IA-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | IA |
| UHC Dual Complete MO-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | MO |
| UHC Dual Complete NE-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | NE |
| UHC Dual Complete KS-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | KS |
| UHC Dual Complete MO-S3 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | MO |
| UHC Dual Complete KS-Q1 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T5 | Yes | $0 | KS |
| UHC Dual Complete TN-S001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| UHC Dual Complete TN-Y001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| UHC Dual Complete TN-Y2 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T5 | Yes | $0 | TN |
| AARP Medicare Advantage from UHC MI-0001 (PPO) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | MI |
| UHC Dual Complete NM-Y1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete NM-S1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete NM-V1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T5 | Yes | $0 | NM |
| UHC Dual Complete AZ-S001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T5 | Yes | $0 | AZ |
| UHC Dual Complete AZ-Y001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T5 | Yes | $0 | AZ |
| UHC Dual Complete VA-Y4 (PPO D-SNP) | Care Improvement Plus South Central Insurance Co. | T5 | Yes | $0 | VA |
| AARP Medicare Advantage from UHC AL-0001 (HMO-POS) | Unitedhealthcare OF THE Midlands, Inc. | T5 | Yes | $0 | AL |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is deflazacort 18 MG Oral Tablet [Jaythari] covered by Medicare Part D?
Yes, deflazacort 18 MG Oral Tablet [Jaythari] is covered by 777 Medicare Part D plans (15.4% of all Part D formularies).
What tier is deflazacort 18 MG Oral Tablet [Jaythari] on Medicare Part D plans?
deflazacort 18 MG Oral Tablet [Jaythari] averages Tier 4 across Part D plans, ranging from Tier 1 to Tier 5.
Does deflazacort 18 MG Oral Tablet [Jaythari] require prior authorization?
91.7% of Part D formularies require prior authorization for deflazacort 18 MG Oral Tablet [Jaythari]. Step therapy: 0%. Quantity limits: 8.3%.
How much does Medicare spend on deflazacort 18 MG Oral Tablet [Jaythari]?
In 2023, total Medicare Part D spending on deflazacort 18 MG Oral Tablet [Jaythari] was $15,369,330, covering 99 beneficiaries. The average spend per beneficiary was $155,245.76.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- dihydroergotamine mesylate 0.5 MG/ACTUAT Metered Dose Nasal Spray T4
- 0.5 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe [Aranesp] T4
- amoxicillin 250 MG / omeprazole 10 MG / rifabutin 12.5 MG Delayed Release Oral Capsule [Talicia] T4
- timolol hemihydrate 5 MG/ML Ophthalmic Solution [Betimol] T4
- bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] T4
- loteprednol etabonate 5 MG/ML Ophthalmic Suspension [Lotemax] T4
Similar prior-authorization rate
- isavuconazonium sulfate 74.5 MG Oral Capsule [Cresemba] 91.7% PA
- {56 (amoxicillin 500 MG Oral Capsule) / 28 (clarithromycin 500 MG Oral Tablet) / 28 (vonoprazan 20 MG Oral Tablet) } Pack [Voquezna 14 Day TriplePak 20;500;500] 91.8% PA
- isavuconazonium sulfate 186 MG Oral Capsule [Cresemba] 91.8% PA
- tretinoin 1 MG/ML Topical Cream 91.6% PA
- deferasirox 500 MG Tablet for Oral Suspension 91.9% PA
- deferasirox 250 MG Tablet for Oral Suspension 91.9% PA